Specialty Pharmacy Support

Partnering With a Specialty Pharmacy

Specialty Pharmacy

Support Every Step of the Way

The Specialty Pharmacy helps with various aspects of treatment, such as:

Helping patients get access to Orenitram
Scheduling nurse visits to get patients started on therapy
Coordinating the delivery of medicine
Offering ongoing assistance through in-person or virtual visits and 24-hour phone support

Orenitram Is Only Available Through 2 Specialty Pharmacy Providers

ACCREDO

CVS

Download, complete, and fax the Referral Form to United Therapeutics Cares™ so your patients can receive support while taking Orenitram.

Download Form

View Example Form

iAssist: Simplify the Process of Getting Patients Started

With just a few clicks, your office can leverage the iAssist platform, which may minimize delays in therapy initiation for your patients.

iAssist is a complimentary, comprehensive solution that simplifies the complex process of getting patients on specialty therapy. With iAssist, healthcare professionals gain access to:

Electronic prescriptions and Referral Forms
Advanced benefit verifications
Real-time electronic prior authorizations
Patient electronic consent
Patient electronic consent
Real-time e-support

Access iAssist

Additional Support Resources

Cost and Financial Support

See how United Therapeutics may help with cost assistance and support for patients taking Orenitram.

United Therapeutics Cares

Discover how a dedicated United Therapeutics Cares Patient Navigator may provide your patients with ongoing, one-on-one education and support.

Video and Resource Library

To access helpful videos, downloadable resources for patients, and recent publications, visit Video and Resource Library.

Continue to Video and Resource Library

SP=Specialty Pharmacy.

IMPORTANT SAFETY INFORMATION

Contraindications

Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

Contraindications

Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Adverse Reactions

In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Warnings and Precautions

Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Drug Interactions

Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
Safety and effectiveness of Orenitram in pediatric patients have not been established.
Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information at www.orenitram.com or call 1-877-UNITHER (1-877-864-8437).